{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:27:25Z","timestamp":1793914045481,"version":"4.8.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>Critically ill children may present with altered pharmacokinetics (PK) and\/or pharmacodynamics (PD), leading to suboptimal dosing of meropenem. We aimed to: 1) investigate meropenem PK in critically ill children, 2) identify factors associated with interindividual PK variability, and 3) evaluate the PK\/PD target attainment rates of current and alternative dosing strategies against the most used PK\/PD targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>Observational PK study with plasma samples taken after the first and steady state doses after receiving IV meropenem. Data were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were performed to evaluate the probability of PK\/PD target attainment for different dosing strategies within the first 48 hours of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>Neonatal and PICU of two Belgian tertiary care hospitals, 2012\u20132020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS:<\/jats:title>\n                    <jats:p>Fifty-four critically ill children (7 d to 14.5 yr old) receiving meropenem infusion at 20\u201340\u2009mg\/kg every 6, 8, or 12 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTIONS:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n                    <jats:p>\n                      Four hundred twenty-three plasma samples were used for population PK analysis. A two-compartment model with allometric scaling and a sigmoidal maturation function accounting for the effects of growth and development best described the data. The typical values for clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution were 13.1, 12.5, 23.9\u2009L\/hr\/70\u2009kg, and 16.3\u2009L\/70\u2009kg, respectively. A loading dose of 40\u2009mg\/kg, followed by a continuous infusion of 60\u2009mg\/kg\/d, was required to achieve 100% of the time the unbound concentration above the minimum inhibitory concentration (MIC) against\n                      <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                      species and\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      (MIC \u2264 2\u2009mg\/L) without compromising safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Standard intermittent dosing regimens (20\u201340\u2009mg\/kg every 8\u2009hr over 0.5\u2009hr) are likely to result in subtherapeutic concentrations, thereby risking therapy failure in critically ill children. A loading dose followed by continuous infusion is suggested for optimal target attainment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pcc.0000000000004046","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:00:10Z","timestamp":1790172010000},"page":"1445-1454","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Meropenem Dosing for Pediatric Critical Care Patients: Multisite Pharmacokinetic Study, 2012\u20132020"],"prefix":"10.1097","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-6091","authenticated-orcid":false,"given":"Anh Thi Van","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Dhont","sequence":"additional","affiliation":[{"name":"Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."},{"name":"Department of Pediatric Intensive Care, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Van Der Heggen","sequence":"additional","affiliation":[{"name":"Department of Neonatology, ZAS Middelheim, Antwerp, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Beel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Verougstraete","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Stove","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium."},{"name":"Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"De Sutter","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vanhaesebrouck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."},{"name":"Department of Neonatal Intensive Care, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9 Vania","family":"Vens","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care, H\u00f4pital Universitaire des Enfants Reine Fabiola, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Paepe","sequence":"additional","affiliation":[{"name":"Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"De Cock","sequence":"additional","affiliation":[{"name":"Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium."},{"name":"Department of Pediatric Intensive Care, Ghent University Hospital, Ghent, Belgium."},{"name":"Department of Pharmacy, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"R1-20261105","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: A review of its use in the treatment of serious bacterial infections.","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"R2-20261105","doi-asserted-by":"crossref","first-page":"119005","DOI":"10.1016\/j.saa.2020.119005","article-title":"Towards understanding of the interaction of certain carbapenems with protein via combined experimental and theoretical approach.","volume":"246","author":"Gadallah","year":"2021","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"R3-20261105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/PCC.0000000000003599","article-title":"Pharmacokinetic factors associated with early meropenem target attainment in pediatric severe sepsis.","volume":"25","author":"Paice","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"R4-20261105","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1097\/PCC.0000000000003698","article-title":"Subtherapeutic meropenem antibiotic exposure in children with septic shock assessed by noncompartmental pharmacokinetic analysis in a prospective dataset.","volume":"26","author":"Bradley","year":"2025","journal-title":"Pediatr Crit Care Med"},{"key":"R5-20261105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11908-018-0613-1","article-title":"Pharmacokinetic\/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients.","volume":"20","author":"Masich","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"R6-20261105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics.","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R7-20261105","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.01008-18","article-title":"Pharmacodynamic target attainment for cefepime, meropenem, and piperacillin-tazobactam using a pharmacokinetic\/pharmacodynamic-based dosing calculator in critically ill patients.","volume":"62","author":"Heil","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20261105","doi-asserted-by":"crossref","first-page":"212608","DOI":"10.7573\/dic.212608","article-title":"Neonatal pharmacology and clinical implications.","volume":"8","author":"Ruggiero","year":"2019","journal-title":"Drugs Context"},{"key":"R9-20261105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","article-title":"Clinical pharmacology studies in critically ill children.","volume":"34","author":"Thakkar","year":"2017","journal-title":"Pharm Res"},{"key":"R10-20261105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","article-title":"Pharmacokinetic alterations associated with critical illness.","volume":"62","author":"Morales Castro","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R11-20261105","doi-asserted-by":"crossref","first-page":"e788","DOI":"10.1097\/PCC.0000000000003727","article-title":"Prevalence and associated explanatory factors for augmented renal clearance in early sepsis: Single-center, retrospective PICU cohort in China, 2022-2023.","volume":"26","author":"Xu","year":"2025","journal-title":"Pediatr Crit Care Med"},{"key":"R12-20261105","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/PCC.0000000000002951","article-title":"Suboptimal beta-lactam therapy in critically ill children: Risk factors and outcome.","volume":"23","author":"Van Der Heggen","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"R13-20261105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/psp4.12611","article-title":"Approaches to handling missing or \u201cproblematic\u201d pharmacology data: Pharmacokinetics.","volume":"10","author":"Irby","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R14-20261105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics.","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R15-20261105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: A quantitative description using weight and postmenstrual age.","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R16-20261105","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jcpt.13369","article-title":"Meropenem use and therapeutic drug monitoring in clinical practice: A literature review.","volume":"46","author":"Steffens","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R18-20261105","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: A retrospective study of \u03b2-lactam concentration-toxicity relationships.","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R19-20261105","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/jac\/dkae274","article-title":"Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.","volume":"79","author":"Morales Junior","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R20-20261105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/INF.0b013e31822e8b0b","article-title":"Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.","volume":"30","author":"Smith","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20261105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bcp.13756","article-title":"Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.","volume":"85","author":"Lonsdale","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20261105","doi-asserted-by":"crossref","first-page":"e0172923","DOI":"10.1128\/aac.01729-23","article-title":"How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children.","volume":"68","author":"Butrague\u00f1o-Laiseca","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20261105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bcp.13160","article-title":"Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?","volume":"83","author":"Germovsek","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R24-20261105","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-025-01495-3","article-title":"Variability in meropenem distribution and clearance in children with sepsis: Population-based pharmacokinetics with assessment of renal biomarkers.","volume":"64","author":"Le","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"R25-20261105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00228-019-02761-7","article-title":"Population pharmacokinetics of meropenem in critically ill children with different renal functions.","volume":"76","author":"Rapp","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R26-20261105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijantimicag.2016.04.025","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.","volume":"48","author":"Kongthavonsakul","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20261105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: A systematic review of current literature.","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R28-20261105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13613-021-00965-8","article-title":"Diagnosing capillary leak in critically ill patients: Development of an innovative scoring instrument for non-invasive detection.","volume":"11","author":"Wollborn","year":"2021","journal-title":"Ann Intensive Care"},{"key":"R29-20261105","first-page":"276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children.","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R30-20261105","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/bcp.15978","article-title":"A physiological approach to renal clearance: From premature neonates to adults.","volume":"90","author":"Holford","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R31-20261105","doi-asserted-by":"crossref","first-page":"e70097","DOI":"10.1002\/jcph.70097","article-title":"From PICU to NICU: Extrapolating meropenem exposure from pediatric to neonatal intensive care patients.","volume":"66","author":"Morales Junior","year":"2026","journal-title":"J Clin Pharmacol"},{"key":"R32-20261105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/phar.2617","article-title":"Scoping review of augmented renal clearance in critically ill pediatric patients.","volume":"41","author":"Rhoney","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R33-20261105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","article-title":"Augmented renal clearance in pediatric intensive care: Are we undertreating our sickest patients?","volume":"35","author":"Dhont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"R34-20261105","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3390\/jcm14051488","article-title":"A real-life study of prolonged meropenem infusion in neonates and children admitted to intensive care units: Are three hours long enough?","volume":"14","author":"Mariani","year":"2025","journal-title":"J Clin Med"},{"key":"R35-20261105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40262-023-01230-w","article-title":"Optimization of \u03b2-lactam dosing regimens in neonatal infections: Continuous and extended administration versus intermittent administration.","volume":"62","author":"Leegwater","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R36-20261105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijantimicag.2015.01.007","article-title":"Subtleties in practical application of prolonged infusion of \u03b2-lactam antibiotics.","volume":"45","author":"De Waele","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R37-20261105","doi-asserted-by":"crossref","first-page":"17211","DOI":"10.1038\/s41598-021-96744-3","article-title":"Optimal loading dose of meropenem before continuous infusion in critically ill patients: A simulation study.","volume":"11","author":"Liebchen","year":"2021","journal-title":"Sci Rep"},{"key":"R38-20261105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","article-title":"\u03b2-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review.","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PCC.0000000000004046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:00:40Z","timestamp":1793912440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PCC.0000000000004046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000004046","relation":{},"ISSN":["1529-7535","1947-3893"],"issn-type":[{"value":"1529-7535","type":"print"},{"value":"1947-3893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}